Rapid-fire Oral Presentation to Highlight Efficacy, Safety, and Quality of Life Outcomes
LOS ANGELES, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that positive data from its Phase 1/2 clinical trial of lonigutamab (an anti-insulin-like growth factor 1 receptor, or IGF-1R) in thyroid eye disease (TED) will be shared in a rapid-fire oral presentation at the 42nd Annual Meeting of the European Society of Ophthalmic Plastic and Reconstructive Surgery (ESOPRS) taking place from September 12-14, 2024 in Rotterdam, Netherlands. Details of the data presentation are as follows:
| Title: | "Preliminary Safety, Efficacy, and Quality of Life Outcomes of Subcutaneous Lonigutamab (Anti-Insulin-Like Growth Factor 1 Receptor [IGF-1R]) from a Phase 1/2 Proof of Concept Study in Patients with Thyroid Eye Disease (TED)" |
| Session Type: | Rapid-fire Oral Presentation |
| Abstract ID: | 24-330 |
| Date/Time: | Saturday, September 14, 2024; 3:45 - 3:50 PM CEST |
| Presenter: | Jwu Jin Khong, M.D. Ph.D., Clinical Senior Lecturer in the Department of Surgery at the University of Melbourne and Consulting Ophthalmologist at the Royal Victorian Eye and Ear Hospital and the Austin Hospital |
"The rapid suppression of IGF-1 receptor signaling observed with lonigutamab could potentially improve clinical outcomes for patients by achieving robust clinical responses with low drug exposures," said Shephard (Shep) Mpofu, M.D., Chief Medical Officer of ACELYRIN. "Importantly, we believe these data are supportive of the potential for subcutaneously-delivered lonigutamab to provide deep and durable responses with convenient, self-administered dosing."
About Lonigutamab
Lonigutamab is a humanized IgG1 monoclonal antibody targeting the IGF-1 receptor and is delivered subcutaneously. Relative to standard of care, lonigutamab binds to a distinct epitope, which results in internalization of the receptor within minutes, and in preclinical binding and functional laboratory assays, it has been shown to be 75-fold more potent. The characteristics of lonigutamab that enable subcutaneous delivery also enable the potential for longer-term, convenient dosing, which can potentially improve depth and durability of clinical response.
About ACELYRIN, INC.
ACELYRIN, INC. (Nasdaq: SLRN) is focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines. ACELYRIN's lead program, lonigutamab, is a subcutaneously delivered monoclonal antibody targeting IGF-1R being investigated for the treatment of thyroid eye disease.
For more information about ACELYRIN, visit us at www.acelyrin.com or follow us on LinkedIn and X.
Forward Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements regarding ACELYRIN's ability to address unmet needs of patients, business plans and potential future benefits of our pipeline. These forward-looking statements are based on ACELYRIN's current plans, objectives and projections, and are inherently subject to risks and uncertainties that may cause ACELYRIN's actual results to materially di?er from those anticipated in such forward-looking statements. Such risks and uncertainties include, without limitation, those associated with the successful completion of development and regulatory activities with respect to ACELYRIN's product candidates, the risk that future results could di?er materially and adversely from early clinical data, and other risks and uncertainties a?ecting ACELYRIN including those described from time to time under the caption "Risk Factors" and elsewhere in ACELYRIN's current and future reports ?led with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and ACELYRIN undertakes no duty to update such information except as required under applicable law.
ACELYRIN Contacts:
Tyler Marciniak
Vice President of Investor Relations and Corporate Affairs
investors@acelyrin.com
media@acelyrin.com
